UK regulators are set to review a proposed label update for Eisai (TYO: 4523) and Biogen’s (Nasdaq: BIIB) Alzheimer’s drug ...

Burdened by competitive pressures for its stalwart multiple sclerosis franchise, Biogen has weathered years of sales declines ...

Lecanemab, currently licensed as a biweekly 10 mg/kg IV infusion, is developed by Eisai and Biogen to address the unmet needs of AD patients. AD, a chronic, progressive disease and the UK’s leading ...

Biogen and Eisai co-commercialize and co-promote the product. Eisai has final decision-making authority. In the EU (excluding the Nordic countries), Eisai and Biogen will co-promote the medicine ...

Last summer, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended against use of the drug, prompting Eisai to express at the time that it was "extremely disappointed." ...

At this time, I'd like to welcome everyone to the Biogen first quarter 2025 earnings call and business update. (Operator Instructions). Today's conference is being recorded. Thank you. I would now ...

In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval ...

Biogen Inc (BIIB) reports a 6% revenue increase driven by new product launches, despite facing competitive pressures in its MS franchise.

Announcing first-quarter results, Biogen CEO Chris Viehbacher admitted that tariffs are “a new topic for us,” but said he ...

Biogen BIIB reported first-quarter 2025 adjusted earnings per share (EPS) of $3.02, which missed the Zacks Consensus Estimate ...

Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped ...

Eisai serves as the lead for Leqembi’s development and regulatory submissions globally, with both partners co-commercialising and co-promoting the product and Eisai having final decision-making ...